Wesley R C, Belardinelli L
Department of Medicine, University of Virginia Medical Center, Charlottesville.
Circulation. 1989 Jul;80(1):128-37. doi: 10.1161/01.cir.80.1.128.
In halothane-nitrous oxide-anesthetized pigs, the effect of the competitive adenosine antagonist, BW-A1433U (a derivative of 1,3-dipropyl-8-phenylxanthine), on postdefibrillation bradyarrhythmia and hemodynamic depression was investigated. In protocol 1, repetitive episodes of ventricular fibrillation lasting 15 seconds before transthoracic DC shock were performed in five animals, before (control) and after the administration of BW-A1433U (5 mg/kg i.v.). An unsuccessful initial shock was immediately followed by a rescue shock of 40 A. In ventricular fibrillation episodes requiring rescue shocks, nine of 19 episodes (47%) exhibited second- or third-degree atrioventricular block at 15 seconds postdefibrillation compared with only one of 16 BW-A1433U episodes (6%). In protocol 2, the effect of BW-A1433U was determined in the presence of dipyridamole, a nucleoside uptake blocker known to potentiate the cardiac actions of adenosine. To counter the hypotensive effect of dipyridamole, methoxamine was continuously infused at 0.015 mg/kg/min i.v. Sequential episodes of ventricular fibrillation lasting 45 seconds were terminated by shocks of 40 A in the presence of methoxamine alone, after dipyridamole (1.5-7.5 mg i.v.), and after BW-A1433U (5 mg/kg i.v.). Over the first 15 seconds postdefibrillation, BW-A1433U significantly (p less than 0.05) increased the number of spontaneous beats (31 +/- 2) and systolic/diastolic blood pressure (111 +/- 4/67 +/- 5 mm Hg; mean +/- SEM; n = 9) compared with both methoxamine (16 +/- 2 beats; 98 +/- 14/52 +/- 12 mm Hg; n = 5) and dipyridamole (8 +/- 3 beats; 58 +/- 11/27 +/- 6 mm Hg; n = 9), respectively. Rapid infusion of BW-A1433U during dipyridamole postdefibrillation periods raised heart rate and blood pressure to preventricular fibrillation levels within 30 seconds. Thus, BW-A1433U can reverse and prevent postdefibrillation bradyarrhythmia and hemodynamic depression. Endogenous adenosine may be an important mediator of postdefibrillation cardiovascular collapse.
在氟烷 - 氧化亚氮麻醉的猪身上,研究了竞争性腺苷拮抗剂BW - A1433U(1,3 - 二丙基 - 8 - 苯基黄嘌呤的衍生物)对除颤后缓慢性心律失常和血流动力学抑制的影响。在方案1中,对5只动物在经胸直流电除颤前(对照)和给予BW - A1433U(5毫克/千克静脉注射)后,进行持续15秒的重复性室颤发作。首次除颤未成功后立即给予40安的抢救性除颤。在需要抢救性除颤的室颤发作中,19次发作中有9次(47%)在除颤后15秒出现二度或三度房室传导阻滞,而BW - A1433U组的16次发作中只有1次(6%)出现。在方案2中,在双嘧达莫存在的情况下测定BW - A1433U的作用,双嘧达莫是一种已知能增强腺苷心脏作用的核苷摄取阻滞剂。为对抗双嘧达莫的降压作用,以0.015毫克/千克/分钟的速度持续静脉输注甲氧明。在仅使用甲氧明、给予双嘧达莫(1.5 - 7.5毫克静脉注射)后以及给予BW - A1433U(5毫克/千克静脉注射)后,通过40安的电击终止持续45秒的连续性室颤发作。在除颤后的前15秒内,与甲氧明(16±2次心跳;98±14/52±12毫米汞柱;n = 5)和双嘧达莫(8±3次心跳;58±11/27±6毫米汞柱;n = 9)相比,BW - A1433U显著(p小于0.05)增加了自发心跳次数(31±2次)和收缩压/舒张压(111±4/67±5毫米汞柱;平均值±标准误;n = 9)。在双嘧达莫除颤后期间快速输注BW - A1433U可在30秒内使心率和血压升高至预防室颤的水平。因此,BW - A1433U可逆转并预防除颤后缓慢性心律失常和血流动力学抑制。内源性腺苷可能是除颤后心血管崩溃的重要介质。